Core Viewpoint - Bio-Techne Corporation is a significant entity in the biotechnology sector, focusing on innovative tools and solutions for life sciences research and clinical diagnostics, competing with major players like Thermo Fisher Scientific and Danaher Corporation [1] Financial Performance - On February 4, 2026, Citigroup upgraded Bio-Techne's stock to a "Buy" rating at approximately $68.89, raising the price target from $70 to $80, indicating confidence in the company's growth potential [2] - Bio-Techne recently held its Q2 2026 earnings call, providing insights into its financial performance, revenue, profit margins, and strategic initiatives, which are crucial for understanding the company's current position and future outlook [3] Stock Performance - Currently, Bio-Techne's stock (TECH) is priced at $68.77, reflecting a 6.41% increase or $4.14, with a daily trading range between $61.70 and $69.92 [4] - Over the past year, the stock has fluctuated, reaching a high of $79.28 and a low of $46.01, indicating the dynamic nature of the stock market [4] Market Capitalization and Trading Volume - Bio-Techne's market capitalization is approximately $10.72 billion, with a trading volume of 3.59 million shares, reflecting the company's size and investor interest in its stock [5]

Financial Performance - Consolidated net sales for the quarter ended December 31, 2025 were $295.9 million, remaining flat compared to the same prior year period, with a 1% decrease for the six months ended December 31, 2025 at $582.4 million [115]. - Organic revenue for the quarter ended December 31, 2025 remained flat, with a favorable foreign currency exchange impact of 2% and an unfavorable impact of 2% from non-recurring prior year revenue from a business held-for-sale [115]. - Consolidated gross margins for the quarter and six months ended December 31, 2025 were 64.6% and 65.1%, respectively, compared to 65.3% and 64.3% for the same prior year periods [116]. - Non-GAAP adjusted net earnings for the quarter ended December 31, 2025 were $72.1 million, with diluted earnings per share of $0.46, compared to $68.1 million and $0.42 in the prior year [127]. Expenses and Cost Management - Selling, general and administrative expenses decreased by 6% to $113.7 million for the quarter and by 4% to $229.9 million for the six months ended December 31, 2025, primarily due to ongoing cost management initiatives [119]. - Research and development expenses decreased by 8% to $23.1 million for the quarter and by 3% to $47.4 million for the six months ended December 31, 2025, while continuing to make strategic growth investments [120]. Segment Performance - Protein Sciences segment net sales for the quarter ended December 31, 2025 were $215.1 million, a 2% increase, while remaining flat for the six months at $417.3 million [121]. - Diagnostics and Spatial Biology segment net sales for the quarter ended December 31, 2025 were $81.2 million, a 4% decrease, with an operating margin of 10.4% compared to 3.9% in the prior year [123]. Taxation - The effective income tax rate for the quarter and six months ended December 31, 2025 was 25.2% and 22.9%, respectively, compared to 18.6% and 17.5% for the same prior year periods [125]. - The forecasted tax rate for the remainder of fiscal 2026 is expected to range from 25% to 29% [126]. - The non-GAAP adjusted tax rate for the quarter ended December 31, 2025, was 22.3%, compared to 21.5% in the same quarter of 2024 [129]. Cash Flow and Capital Management - As of December 31, 2025, cash and cash equivalents were $172.9 million, an increase from $162.2 million as of June 30, 2025 [130]. - The company generated $110.0 million from operating activities in the six months ended December 31, 2025, down from $148.2 million in the same period of 2024, primarily due to changes in cash payment timing [133]. - Capital expenditures for fixed assets for the six months ended December 31, 2025, were $11.3 million, compared to $16.0 million in 2024, with an expected $18 million for the remainder of fiscal 2026 [135]. - The company paid cash dividends of $24.9 million during the six months ended December 31, 2025, slightly down from $25.4 million in 2024 [138]. - The company made repayments of $86.0 million on its long-term debt during the six months ended December 31, 2025, compared to $19.0 million in the same period of 2024 [140]. - The company has a line-of-credit of $740 million available as of December 31, 2025, governed by a Credit Agreement maturing on August 31, 2027 [130]. - The company expects to meet its cash and working capital requirements for at least the next 12 months through available cash and generated cash from operations [132]. Acquisitions - The company acquired 19.9% of Wilson Wolf for $232 million in fiscal 2023, with a future obligation to acquire the remaining 80.1% by December 31, 2027, contingent on financial milestones [131]. Asset Management - The company received $4.6 million for assets held-for-sale during the six months ended December 31, 2025, compared to $1.8 million in 2024 [137].

Adjusted EPS was $0.46, up 10% year over year, including a favorable $0.04 impact from foreign exchange. GAAP EPS was $0.24, compared with $0.22 a year earlier.CFO Jim Hipple quantified the impact, saying that excluding the timing effect from those two customers, organic growth would have been 4% for the quarter. Hipple added that the company also benefited from a large OEM commercial supply reagent order that historically landed in fiscal Q3 but shifted into Q2, contributing about 1% to growth in both Prot ...

Key Takeaways TECH posted Q2 adjusted EPS of 46 cents and revenues of $295.9M, beating consensus estimates. Bio-Techne saw Protein Sciences grow 2% while Diagnostics and Spatial Biology sales fell 4% year over year. TECH expanded operating margin 244 bps to 18.4% as operating profit rose to $54.5M. Bio-Techne Corporation (TECH) reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 46 cents, which surpassed the Zacks Consensus Estimate by 8.2%. The bottom line was up 9.5% on a year-over-ye ...

For the quarter ended December 2025, Techne (TECH) reported revenue of $295.88 million, down 0.4% over the same period last year. EPS came in at $0.46, compared to $0.42 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $292.03 million, representing a surprise of +1.32%. The company delivered an EPS surprise of +8.24%, with the consensus EPS estimate being $0.43.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...

Bio-Techne (NasdaqGS:TECH) Q2 2026 Earnings call February 04, 2026 09:00 AM ET Company ParticipantsBrandon Couillard - Managing DirectorDan Arias - Managing DirectorDavid Clair - VP of Investor RelationsJim Hippel - CFOKim Kelderman - President and CEOPatrick Donnelly - Managing Director of Equity ResearchConference Call ParticipantsDan Leonard - Managing Director of Research AnalystMatt Larew - AnalystPuneet Souda - Senior Research AnalystNone - AnalystOperatorThank you for your continued patience. Your me ...

Bio-Techne (NasdaqGS:TECH) Q2 2026 Earnings call February 04, 2026 09:00 AM ET Company ParticipantsBrandon Couillard - Managing DirectorDan Arias - Managing DirectorDavid Clair - VP of Investor RelationsJim Hippel - CFOKim Kelderman - President and CEOPatrick Donnelly - Managing Director of Equity ResearchConference Call ParticipantsDan Leonard - Managing Director of Research AnalystMac Etoch - Equity Research AnalystMatt Larew - AnalystPuneet Souda - Senior Research AnalystOperatorThank you for your contin ...

Bio-Techne (NasdaqGS:TECH) Q2 2026 Earnings call February 04, 2026 09:00 AM ET Speaker3Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time throughout the event today, please press star zero and a member of our team will be happy to help you. Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time throughout the call today, please press star zero and a member of our team will be happy to help you. Good m ...

Techne (TECH) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +8.24%. A quarter ago, it was expected that this maker of medical testing and diagnostic products would post earnings of $0.42 per share when it actually produced earnings of $0.42, delivering no surprise.Over the last four ...

Biotech firm Bio-Techne beat analysts' estimates for second-quarter revenue and profit on Wednesday, helped by robust demand for its products used in drug development. ...